Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 18;14:1245708. doi: 10.3389/fimmu.2023.1245708

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Liu, Chen, Zhao, Boland, Ting, Lockwood, McKenzie, Kench, Vadas, Gamble and McCaughan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of combination CD5-2 and anti-PD1 on liver tumour formation. DEN was injected intraperitoneally once into wildtype C57BL/6 male pups at postnatal day 12-14. Control or CD5-2 Blockmir was administered intravenously every 2 weeks (30mg/kg) in combination with control Ig or anti-mouse PD1 mAb was administered intraperitoneally every 3 days (250µg) for a total of 8 weeks (weeks 30-38 of age). (A-D) Liver tissues were harvested at 38 weeks. Visible tumours on the surface of each liver were counted and their size measured. Graphs of (A) liver tumour number, (B) maximum tumour size, and (C) liver tumour volume. (D) Macroscopic images of visible liver tumour in each treatment group. (E) Proportion of liver tumours classified by two expert liver pathologists as hepatocellular carcinoma (HCC), high-grade dysplastic (HGD) nodules and low-grade dysplastic (LGD) nodules in DEN-treated mice from no treatment vs. CD5-2 plus anti-PD1 groups. Data are expressed as mean ± SEM, n=20 each group. Scale bar = 0.5cm * = P<0.05.